Literature DB >> 8428333

Endocrine therapy of advanced carcinoma of the prostate.

F Daneshgari1, E D Crawford.   

Abstract

Increasing evidence suggests that growth of the prostatic tissue is regulated by a network of hormones and growth factors, in which androgens play the prominent role. Hormonal manipulation remains the core of treatment for locally advanced and metastatic prostate cancer. Achievement of a complete androgen blockade, by surgical or medical means or a combination of both, offers superior results in palliative management of advanced disease. Management of hormonal refractory cancer, however, remains a challenge to clinicians.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8428333     DOI: 10.1002/1097-0142(19930201)71:3+<1089::aid-cncr2820711431>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  Androgen deprivation causes up-regulation of androgen receptor transcript in the rat prostate.

Authors:  V L Kumar; P K Majumder; V Kumar
Journal:  Mol Cell Biochem       Date:  1997-06       Impact factor: 3.396

2.  A multidisciplinary approach to the management of hormone-refractory prostate cancer.

Authors:  Samir S Taneja
Journal:  Rev Urol       Date:  2003

3.  A multidisciplinary approach to the management of hormone-refractory prostate cancer.

Authors:  Samir S Taneja
Journal:  Rev Urol       Date:  2003

4.  Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer.

Authors:  Z Kolár; P G Murray; K Scott; A Harrison; B Vojtĕsek; J Dusek
Journal:  Mol Pathol       Date:  2000-02

5.  Growth inhibition of DMBA-induced rat mammary carcinomas by the antiandrogen flutamide.

Authors:  G Boccuzzi; E Tamagno; E Brignardello; M Di Monaco; M Aragno; O Danni
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

6.  A phase II trial with new triptorelin sustained release formulations in prostatic carcinoma.

Authors:  N K Minkov; B I Zozikov; Z Yaneva; P A Uldry
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

Review 7.  Targeting vasculature in urologic tumors: mechanistic and therapeutic significance.

Authors:  Shinichi Sakamoto; A Jacqueline Ryan; Natasha Kyprianou
Journal:  J Cell Biochem       Date:  2008-02-15       Impact factor: 4.429

8.  Maximal androgen blockade in combination with methotrexate for treatment of metastatic prostate cancer.

Authors:  P Sagaster; J Flamm; M Micksche; E Fritz; G Donner; H Ludwig
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 9.  Therapeutic value of quinazoline-based compounds in prostate cancer.

Authors:  Johnathan Bilbro; Matthew Mart; Natasha Kyprianou
Journal:  Anticancer Res       Date:  2013-11       Impact factor: 2.480

10.  Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells.

Authors:  E R Sherwood; J L Van Dongen; C G Wood; S Liao; J M Kozlowski; C Lee
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.